Abstract
The synthesis and the degradation of gap junctions involve multiple steps that may provide targets for the modulation of intercellular communication. Many studies using cultured cells have examined the effects of inhibitors of protein synthesis, trafficking, or degradation upon connexins. Similarly, activators or inhibitors of various protein kinases have been shown to affect connexin assembly or proteolysis. These studies have helped to elucidate the connexin lifecycle. But, because of their lack of specificity for gap junction proteins, these agents would be expected to have limited therapeutic utility and to produce several deleterious side effects. However, more selective agents are being developed based on specific features of the connexin sequences. Molecular genetic approaches have been used to introduce wild-type connexins to increase intercellular communication in otherwise poorly coupled cells. Decreased intercellular communication may be obtained by application of peptides that mimic the extracellular loops and may prevent docking of hemi-channels. Alternatively, introducing mutant connexins that interfere with the oligomerization/export of endogenous connexins or with channel function by formation of non-functional heteromeric hemi-channels can also reduce intercellular communication.
Current Drug Targets
Title: Gap Junction Synthesis and Degradation as Therapeutic Targets
Volume: 3 Issue: 6
Author(s): Eric C. Beyer and Viviana M. Berthoud
Affiliation:
Abstract: The synthesis and the degradation of gap junctions involve multiple steps that may provide targets for the modulation of intercellular communication. Many studies using cultured cells have examined the effects of inhibitors of protein synthesis, trafficking, or degradation upon connexins. Similarly, activators or inhibitors of various protein kinases have been shown to affect connexin assembly or proteolysis. These studies have helped to elucidate the connexin lifecycle. But, because of their lack of specificity for gap junction proteins, these agents would be expected to have limited therapeutic utility and to produce several deleterious side effects. However, more selective agents are being developed based on specific features of the connexin sequences. Molecular genetic approaches have been used to introduce wild-type connexins to increase intercellular communication in otherwise poorly coupled cells. Decreased intercellular communication may be obtained by application of peptides that mimic the extracellular loops and may prevent docking of hemi-channels. Alternatively, introducing mutant connexins that interfere with the oligomerization/export of endogenous connexins or with channel function by formation of non-functional heteromeric hemi-channels can also reduce intercellular communication.
Export Options
About this article
Cite this article as:
Eric C. Beyer and Viviana M. Berthoud , Gap Junction Synthesis and Degradation as Therapeutic Targets, Current Drug Targets 2002; 3 (6) . https://dx.doi.org/10.2174/1389450023347245
DOI https://dx.doi.org/10.2174/1389450023347245 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Transcriptional Regulation of the Human CYP2C Genes
Current Drug Metabolism Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis
Current Molecular Medicine DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics of Opioids for the Treatment of Acute Maternal Pain During Pregnancy and Lactation
Current Drug Metabolism Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Protein-based Strategies of Molecular Therapy in Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Disorders of Mineral Metabolism in the Newborn
Current Pediatric Reviews Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Epidemiology of NHP-Drug Interactions: Identification and Evaluation
Current Drug Metabolism Targeting Heat Shock Proteins in Tauopathies
Current Alzheimer Research Teaching Vaccine Safety Communication to Medical Students and Health Professionals
Current Drug Safety Vaccine Ingredients: Components that Influence Vaccine Efficacy
Mini-Reviews in Medicinal Chemistry Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients
Recent Patents on Anti-Infective Drug Discovery Ketamine as Antidepressant? Current State and Future Perspectives
Current Neuropharmacology Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody
Current Pharmaceutical Design